Skip to content

Reduced-dose glucocorticoid as prophylaxis for serum sickness after ATG/ALG therapy in patients with aplastic anemia: a prospective, multi-center, non-inferior, random study

Reduced-dose glucocorticoid as prophylaxis for serum sickness after ATG/ALG therapy in patients with aplastic anemia: a prospective, multi-center, non-inferior, random study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087735
Enrollment
Unknown
Registered
2024-08-02
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aplastic anemia

Interventions

Usual dose group:After the 5-days ATG/ALG transfusion period, subjects will continue to receive usual glucocorticoid therapy equivalent to1 mg/kg/d methylprednisolone, tapring from Day 15 to Day 28.
Reduced dose group:After the 5-days ATG/ALG transfusion period, subjects will receive half-dose glucocorticoid therapy equivalent to 0.5 mg/kg/d methylprednisolone, tapring from Day 6 to Day 20.

Sponsors

The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. To meet the diagnostic criteria of severe AA or transfusion-dependent non-severe AA. 2. Age between 2-65 years; 3. Body weight >12 kg; 4. Ineligible for MSD allo-HSCT 5. Subjects have voluntarily signed an informed consent form, understanding the purpose and procedure of clinical study and voluntarily complying with the trial requirements.

Exclusion criteria

Exclusion criteria: 1. Age =65 years; 2. Myocardial infarction, uncontrolled angina, uncontrolled heart failure, uncontrolled hypertension,arteriovenous thrombosis; 3. Cocurrent endocrine disese: diabetes mellitus, hyper/hypothyroidism 4.Severe osteoporosis, necrosis of the femoral head 5.Active viral hepatitis 6. Uncontrolled active infection 7.The physical status score of the Eastern Cancer Collaboration Group (ECOG) >2 points 8.Aspartic aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal 9.Creatinine level >= 2.5 times the upper limit of normal 10. Subjects with any other condition or circumstance that would, in the opinion of the Investigator, make the subject unsuitable for participation in this clinical study.

Design outcomes

Primary

MeasureTime frame
Incidence of serum sickness;

Secondary

MeasureTime frame
Occurrence and outcomes of serum sickness of different severity;Duration of serum sickness ;Incidence of glucocorticoid-related adverse reactions;Treatment response;Survival rate;

Countries

China

Contacts

Public ContactGuangsheng He

The First Affiliated Hospital with Nanjing Medical University

heguangsheng1972@sina.com+86 153 1205 2798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026